Acute promyelocytic leukemia (APL) cells invariably express aberrant fusion proteins involving the retinoic acid receptor ␣ (RAR␣). The most common fusion partner is promyelocytic leukemia protein (PML), which is fused to RAR␣ in the balanced reciprocal chromosomal translocation, t(15;17)(q22:q11). Expression of PML͞ RAR␣ from the cathepsin G promoter in transgenic mice causes a nonfatal myeloproliferative syndrome in all mice; about 15% go on to develop APL after a long latent period, suggesting that additional mutations are required for the development of APL. A candidate target gene for a second mutation is FLT3, because it is mutated in approximately 40% of human APL cases. Activating mutations in FLT3, including internal tandem duplication (ITD) in the juxtamembrane domain, transform hematopoietic cell lines to factor independent growth. FLT3-ITDs also induce a myeloproliferative disease in a murine bone marrow transplant model, but are not sufficient to cause AML. Here, we test the hypothesis that PML͞RAR␣ can cooperate with FLT3-ITD to induce an APL-like disease in the mouse. Retroviral transduction of FLT3-ITD into bone marrow cells obtained from PML͞RAR␣ transgenic mice results in a short latency APL-like disease with complete penetrance. This disease resembles the APL-like disease that occurs with long latency in the PML͞RAR␣ transgenics, suggesting that activating mutations in FLT3 can functionally substitute for the additional mutations that occur during mouse APL progression. The leukemia is transplantable to secondary recipients and is ATRA responsive. These observations document cooperation between PML͞RAR␣ and FLT3-ITD in development of the murine APL phenotype.
A cute promyelocytic leukemia (APL) comprises 5-10% of cases of AML and is almost always associated with rearrangement of the retinoic acid receptor ␣ (RAR␣) gene as a consequence of balanced reciprocal chromosomal translocations. The t(15;17)(q22;q11.2) is the most common such translocation and most APL cells with this translocation express both the promyelocytic leukemia (PML)͞RAR␣ and RAR␣͞PML fusion proteins. Mouse models and cell culture assays have demonstrated that the PML͞RAR␣ fusion protein contributes to the leukemic phenotype in part by inhibiting differentiation and promoting survival of hematopoietic progenitor cells (1) (2) (3) (4) (5) (6) .
Data from murine models and analysis of human APL genotypes indicate that the PML͞RAR␣ fusion protein is necessary, but not sufficient for the APL disease phenotype. Transgenic mice expressing PML͞RAR␣ under the control of the cathepsin G promoter can develop acute myeloid leukemia (AML) with many of the features of APL (1, 2, 7, 8) . All transgenic animals expressing this transgene display a myeloproliferative syndrome characterized by elevated numbers of myeloid cells in the marrow and spleen. After a latency of 6-13 months, 15-20% of animals develop an APL-like disease. However, the penetrance increases to about 60% when both the PML͞RAR␣ and the reciprocal RAR␣͞PML cDNAs are expressed in early myeloid cells (1, 7) . Progression to leukemia in this model system is often associated with acquisition of additional cytogenetic abnormalities (3, 8) . The long latency, incomplete penetrance, and cytogenetic changes accompanying disease progression strongly suggest that additional mutations are required for the development of APL in the murine models.
In human APL, all-trans-retinoic acid (ATRA) directly targets the PML͞RAR␣ fusion protein (9-11), but does not induce long-term disease-free survival unless it is combined with intensive induction chemotherapy (10, (12) (13) (14) . Although there are several possible explanations for the inability of ATRA to cure APL, it is plausible that there are second mutations present that are not ATRA sensitive. Perhaps the most convincing evidence to support the hypothesis that additional mutations contribute to the APL phenotype has been recent reports of a high frequency of activating mutations in the FLT3 receptor tyrosine kinase in APL. Approximately 37% of t(15;17) APL patients have mutations that constitutively activate the FLT3 tyrosine kinases (15) .
These genetic and epidemiological data suggest a role for mutant FLT3 as a second event in pathogenesis of APL. Internal tandem duplications (ITDs) in FLT3 (FLT3-ITD) are found in 27% of all AML cases (16) (17) (18) and the frequency is even higher (37%) in APL patients (15) . FLT3-ITDs are constitutively activated and can confer factor-independent growth to 32D (19, 20) or Ba͞F3 cells (21) (22) (23) . Furthermore, when transduced into primary mouse bone marrow cells, FLT3-ITDs induce a myeloproliferative disease in recipient mice (23) with normal maturation and differentiation of myeloid lineage cells. These data indicate that although FLT3-ITD is not sufficient to cause an AML phenotype in this model, it does cause myeloid cell proliferation or survival.
Based on these considerations, and the high frequency of FLT3-ITD mutations in human APL, we have tested the hypothesis that FLT3-ITD cooperates with PML͞RAR␣ by using a murine model. Our experimental approach uses retroviral transduction of FLT3-ITD into bone marrow cells derived from cathepsin G-PML͞ RAR␣ transgenic mice (1), followed by transplantation of transduced cells into lethally irradiated syngeneic recipient mice to test for development of leukemia. We present data consistent with cooperation between PML͞RAR␣ and FLT3-ITD in the development of APL. These findings have important implications for pathogenesis of APL and targeted molecular therapy of APL patients with an activated FLT3 gene.
Methods

Mouse Strains and Bone Marrow Transplantation (BMT).
Cathepsin G-PML͞RAR␣ transgenic mice were created on a mixed B6ϫC3H background and maintained by random interbreeding with each other (1, 7) . Mice were genotyped either by Southern analysis for the presence of the transgene as described (1, 7) or PCR. A 360-bp PCR product was obtained from the PML͞RAR␣ transgene and a 312-bp product from the RAR␣͞PML transgene by using the primer pairs PF, 5Ј-AGGAAGGTCATCAAGATGGAGTC, and PR2, 5Ј-GAAGCCCTTGCAGCCCTCACA, or RF, 5Ј-CT-GGGGCTAGGCGGTCCATCCA, and RR, 5Ј-GACCACTCTC-CAGCACCAGCTTCCAG, respectively. BMT assays were carried out as described (23) (24) (25) . The FLT3-ITD construct used was FLT3-ITD͞51 (23) with enhanced green fluorescent protein (EGFP) expressed from an internal ribosomal entry site (IRES) in the murine stem cell virus (MSCV). EGFP-MSCV was a kind gift from W. Pear, University of Pennsylvania, Philadelphia (26) , and transduction efficiency as measured by EGFP fluoresence was between 5% and 10% at 24 and 2 h post-spin infections 1 and 2, respectively. A total of 1 ϫ 10 6 cells were injected into the lateral tail vein of lethally irradiated (2 ϫ 535 cGy) female (B6ϫC3H)F 1 recipient mice. These recipients were chosen as they will readily accept grafts from either B6 or C3H strains. For secondary transplants, mice were sublethally irradiated (535 cGy) and transplanted with 1 ϫ 10 6 spleen cells. ATRA pellets (10 mg, 60-day release, Innovative Research of America) were implanted s.c.
Analysis of Transplanted Mice. Peripheral blood was collected from the retro-orbital plexus by using a heparinized capillary, and blood smears were prepared and total and differential blood counts were determined (ADVIA 120 hematology system, Bayer). The spleen, liver, heart, lungs, intestine, kidneys, lymph nodes, and hindlimb bones were collected in 10% neutral buffered formalin for preparation of histological sections as described (23) . Single cell suspensions of spleen and bone marrow were stained with allophycocyanin-conjugated antibodies to Gr-1, Mac-1, or CD4 and phycoerythrin-conjugated antibodies to Mac-1, c-Kit and CD8␣ as described (23) .
Southern Analysis. DNA (20 g) was digested with EcoRI and Southern hybridization was performed exactly as described (23) . The EGFP probe was a 750-bp fragment isolated by using a NcoI͞SalI digest from EGFP-murine stem cell virus. The human cathepsin G probe was a 550-bp fragment spanning exons 2 and 3.
Colony Assays. Colony assays were performed in RPMI media containing IL-3 (6 ng͞ml), IL-6 (10 ng͞ml), stem cell factor (10 ng͞ml), 10% FCS, and 10% bovine citrated plasma. Cells were diluted in this medium, which was clotted by the addition of 10 units͞ml of thrombin per ml and immediately transferred into cell culture dishes. Cells were seeded over a range of 1 ϫ 10 4 -2 ϫ 10 5 cells͞ml, and assays were harvested and analyzed at 5-7 days. Clotted colonies were compressed onto slides through silk mesh and dried with Whatman paper. Colonies were stained with Wright and Giemsa. ATRA diluted in 0.1% EtOH was included at 10 Ϫ6 M where indicated.
Results
Neither PML͞RAR␣ Nor FLT3-ITD Independently Induce Acute Leukemia in a Murine BMT Model. To assess the potential for cooperative effects between FLT3-ITD and PML͞RAR␣, we used the single PML͞RAR␣ transgenic model because it has low disease penetrance and long latency (1) . Therefore, any change in disease latency or penetrance caused by FLT3-ITD would be clearly evident. As a control, we initially characterized the phenotype of mice transplanted with bone marrow cells derived from PML͞ RAR␣ transgenic mice. In the PML͞RAR␣ asymptomatic transgenics, the white blood cell count shows a slight elevation in mature myeloid cells caused by elevated promyelocyte counts as described (1) . Cells from healthy 10-week-old, age-matched transgenic donors were pooled and transduced with a retroviral vector control containing the EGFP gene expressed from an internal ribosomal entry site. We found that transplantation of EGFP-transduced PML͞ RAR␣ transgenic bone marrow cells into lethally irradiated (B6ϫC3H)F 1 recipients resulted in a similar disease latency, low penetrance, and APL-like phenotype as the reported transgenic model (1) , validating the use of the adoptive transfer model for these experiments. After 100 days APL developed in some animals transplanted with these cells. Thus, when the age of the donor mice was taken into account, disease latency was comparable to Ͼ180-day latency observed in unmanipulated PML͞RAR␣ transgenic animals. This BMT protocol involves treating donor mice with 5-fluorouracil (5-FU) to induce cycling of hematopoietic progenitor cells, which renders them susceptible to retroviral transduction. Although 5-FU treatment may have effects on progenitor cells in other genetic backgrounds (27), we did not find a statistically significant change in disease latency when recipients of cells from 5-FU-treated and untreated animals were compared (data not shown).
FLT3-ITD mutations alone are also not sufficient to induce acute leukemia in the murine BMT models. FLT3-ITD expression induces a myeloproliferative disease with a median latency of 55 days in BALB͞c mice (23) . In contrast, we observed that (B6ϫC3H)F 1 recipients of FLT3-ITD-transduced bone marrow (mixed B6͞C3H) pooled from wild-type littermates of the transgenics developed features of a T cell lymphoblastic lymphoma with a median latency of 100 days (Fig. 1A) . Diseased animals had thymic involvement and associated mediastinal lymphadenopathy, but did not typically display leukocytosis, hepatomegaly, or splenomegaly (Table 1) . Histopathologic analysis showed features characteristic of lymphoblastic lymphoma consisting of small to intermediate-sized immature lymphoid cells with dispersed chromatin and scant cytoplasm (Fig. 2B Inset) . Immunophenotypic analysis of spleen cells (Fig. 3) and the thymic and mediastinal masses (data not shown) by flow cytometry demonstrated increases in CD4 ϩ CD8 ϩ and CD8 ϩ cells. Taken together, these data indicate that in contrast with data from BALB͞c backgrounds, in the B6͞C3H background FLT3-ITD causes a long latency T cell lymphoblastic lymphoma-like disease, which was not transplantable to secondary recipients with 10 6 spleen cells (Table 2) . Although the basis for the strain-specific difference in latency and phenotype is not known, similar observations of strain-specific influences have been previously reported (28) . The phenotype observed with FLT3-ITD alone provides a clear contrast for the comparison of the contribution of the FLT3-ITD allele to PML͞RAR␣ leukemic phenotype.
PML͞RAR␣ and FLT3-ITD Cooperate to Induce a Short Latency APL-Like
Disease with Complete Penetrance. PML͞RAR␣ transgenic cells were transduced with FLT3-ITD and introduced into lethally irradiated (B6ϫC3H)F 1 recipients to determine the effect of the combination of both oncogenes on the disease phenotype. Control experiments with retroviral transduction of internal ribosomal entry site (IRES)-EGFP into transgenic cells and FLT3-ITD-IRES-EGFP into cells from wild-type littermates were also performed. In three independent experiments, the combination of FLT3-ITD and PML͞RAR␣ (F3ϩPR) induced an APL-like disease in 100% of animals, with a significantly reduced latency compared with EGFP and PML͞RAR␣ (EGFPϩPR) (Fig. 1B) . As expected, a few animals with EGFPϩPR eventually developed APL, which was compared with the APL phenotype induced by F3ϩPR (see below).
Animals that had F3ϩPR disease displayed leukocytosis, splenomegaly, and hepatomegaly, but did not have mediastinal lymphadenopathy or thymic involvement as was seen with FLT3-ITD in wild-type cells (Table 1) . Histopathologic examination of the spleens of F3ϩPR (Fig. 2) showed a high proportion of immature myeloid cells, in contrast to wild-type or FLT3-ITD-only spleens. Hepatomegaly, associated with infiltration of immature myeloid cells, and bone marrow hyperplasia comprised of immature myeloid lineage cells, was also observed in F3ϩPR animals. There was also a consistent increase in the proportion of eosinophilic myeloid forms in the spleen, bone marrow, and peripheral blood of F3ϩPR mice compared with controls. Consistent with the histopathologic analysis, flow cytometric analysis of spleen cells (Fig. 3) (Fig. 3) , corresponding to the CD34ϩ Gr-1 low population described previously (1) .
Only a fraction of cells are transduced by retrovirus in the BMT assay, so a critical corollary of the hypothesis that FLT3-ITD mutations cooperate with PML͞RAR␣ to cause an APL phenotype is that the FLT3-ITD provirus should be present in leukemic cells. This was demonstrated with Southern blot analysis using a probe for the FLT3-ITD retrovirus (EGFP), where several positive bands were observed in each primary recipient (Fig. 4, lanes 1-6) . Southern analysis indicates that the disease is oligoclonal in the primary animals, and clonal selection occurs upon transplanation to secondary recipients. Presence of the PML͞RAR␣ transgene was demonstrated with a cathepsin G probe and was also an indication of equivalent DNA loading.
The FLT3 ؉ PML͞RAR␣ Disease Is Transplantable to Secondary Recipients. The APL-like leukemia from F3ϩPR animals was transplantable into sublethally irradiated secondary recipients (Table 2) , as was the less frequently occurring EGFPϩPR disease, as previously reported (1) . The disease latency in secondary recipients of F3ϩPR and EGFPϩPR leukemic cells (spleen) was comparable; all animals that received 10 6 cells derived from either leukemic EGFPϩPR or F3ϩPR mice developed disease within 60 days. The disease latency was shorter in tertiary transplant recipients (Table  2) , which may indicate selection for initiating cells. Finally, cells from asymptomatic EGFPϩPR mice, or cells from FLT3-ITD mice with the lymphoid disease, did not cause leukemia in secondary recipients with a follow-up of 150 days.
Interestingly a slightly greater degree of myeloid maturation, as judged by morphology and surface antigen expression, was noted in primary F3ϩPR disease compared with the EGFPϩPR disease (Figs. 2 and 3 ), although this distinction was not evident after transfer to 2°or 3°recipients. Examination of the spleen (Fig. 4B) showed the highest proportion of immature myeloid cells in tertiary recipients. Flow cytometry (Fig. 4A) 
The survival times are taken from the Kaplan-Meier survival plots (Fig. 1) . The n value in each field represents the number of animals for which that particular analysis was performed. 4C, lanes 7-9) from an oligoclonal background seen in the primary transplant mice (Fig. 4C, lane 6) . (1, 2, 7). ATRA treatment induced differentiation into mature neutrophils but did not result in proliferation (Fig.  5) . In contrast, untreated cells continued to grow in compact colonies with a low rate of spontaneous differentiation, as reported (1, 2, 7). The morphology of the cells without ATRA was less differentiated than those growing in the presence of ATRA as seen with higher magnification (Fig. 5 Insets) . Both the F3ϩPR and EGFPϩPR cells responded equally well to ATRA, indicating that the F3ϩPR cells expressed PML͞ RAR␣ and retained ATRA sensitivity.
Response of the disease to ATRA was also tested in vivo. Mice with a secondary disease resulting from a transplant of either 10 6 F3ϩPR or EGFPϩPR cells were given 10-mg, 60-day, slow-release ATRA pellets 19 days after transplant (when splenomegaly could be detected by palpation). At 29 days F3ϩPR animals with ATRA pellets had a marked reduction in splenomegaly (90-100 mg, n ϭ 3) compared with untreated controls (600-1,100 mg, n ϭ 3). Similiarly, at 37 days EGFPϩPR animals with ATRA pellets showed a reduction in spleen size (40-55 mg, n ϭ 4) compared with untreated controls (469-564 mg, n ϭ 2). ATRA-treated animals also showed a shift toward normal in the white blood cell differential and a dramatic reduction in histological evidence of leukemia in the spleen (data not shown). This finding further indicates that the F3ϩPR disease depends on PML͞RAR␣ and remains equally responsive to the effects of ATRA. Animals designated P͞RϩITD 1°A, B, C represent different primary mice with AML induced by PML͞RAR␣ and FLT3-ITD. P͞RϩITD 2°A represents an animal with AML caused by transplantation of cells from P͞RϩITD 1°A. P͞R AML 1°and P͞R asym. 1°represent animals transplanted with PML͞RAR␣ transgenic cells that either developed AML or remained asymptomatic, respectively. Wt ϩ ITD 1°represents an animal with lymphoid disease induced by FLT3-ITD in wild-type cells. Cells from the spleen were transplanted in each case.
Discussion
We have tested the potential of the mutant proteins FLT3-ITD and PML͞RAR␣ to cooperate to cause APL in a murine BMT assay. The combination of FLT3-ITD and PML͞RAR␣ (F3ϩPR) induces an APL-like leukemia in recipient mice over a period of 7-23 weeks with 100% penetrance. In contrast, the latency is longer and the frequency of disease is lower in recipients of the EGFPtransduced PML͞RAR␣ (EGFPϩPR) bone marrow and corresponds to the 15-30% penetrance level of APL reported (1) for unmanipulated transgenic mice (Fig. 1 A) . Alone, FLT3-ITD leads to a lymphoid disease in the mixed B6ϫC3H background used for these experiments (Fig. 1B) . Therefore, we conclude that the observed disease reflects a cooperative rather than an additive effect between FLT3-ITD and PML͞RAR␣.
The APL syndromes induced by either F3ϩPR or EGFPϩPR are very similar. The animals display leukocytosis, splenomegaly, and hepatomegaly (Table 1) . Histological and surface marker analysis suggests that the expanded cell populations are comprised of immature myeloid cells (Figs. 2 and 3) . The diseases are transplantable to secondary recipients, indicating that they are fully transformed (Table 2) . Finally, APL cells from both sets of mice respond in vitro and in vivo to the differentiating effects of ATRA. These data suggest that the FLT3-ITD can functionally substitute for the additional mutations occurring to produce spontaneous leukemias in the PML͞RAR␣ transgenic mice.
Although the phenotypes were very similar, primary animals with the F3ϩPR had a higher proportion of mature cells (Gr-1 Differential cell counts show a consistent increase in neutrophils and eosinophils in the F3ϩPR peripheral blood, whereas the EGFPϩPR samples have more variability, with increased monocytes, eosinophils, or both, often seen in addition to increased neutrophils. This may reflect transduction of FLT3-ITD into a distinct subset of progenitor cells, such as proeosinophils, from total bone marrow of the transgenic mice. It may also reflect differences between the mouse BMT system and the natural evolution of leukemia in humans, as the murine APL model (1, 7) , in contrast to human APL, exhibits some differentiation to mature neutrophils. Below each FACS profile is a histological section of the spleen from a primary, secondary, or tertiary animal, stained with hematoxylin and eosin (ϫ500 magnification). Southern analysis of cells from primary (lanes 1-6) and secondary (lanes 7-9) recipients is shown; each lane represents an individual mouse. The animal represented in lane 6 was the source of primary cells used for secondary transplantation (lanes 7-9), hybridized with EGFP. These data were generated on a single blot. The blot was rehybridized with cathepsin G as a control for DNA loading. Cumulatively, these data indicate that although there are subtle differences in the phenotype between the F3ϩPR and EGFPϩPR diseases, FLT3-ITD cooperates with PML͞RAR␣ to cause APL.
We favor the hypothesis that AML is the consequence of cooperation between at least two classes of mutation, one that impairs hematopoietic differentiation and a second that confers a proliferative and͞or survival advantage. Several lines of evidence support this model. A spectrum of AML patients have been identified where two gene rearrangements were observed involving mutation of a transcription factor and constitutive activation of a tyrosine kinase. Examples include AML͞ETO or NUP98͞HOXA9 translocations in combination with TEL͞PDGF␤R or BCR͞ABL, respectively (29, 30) . Avian model systems also have demonstrated mutations in both cell surface receptors and nuclear factors in leukemia development (31, 32) . In addition, although activated kinases and altered function of hematopoietic transcription factors are associated with leukemia (33), neither mutation alone is sufficient to induce AML in mouse BMT models (24, 34, 35) . Cooperativity of AML1͞EVI1 or NUP98͞HOXA9 with BCR͞ABL in leukemia progression has been recently reported in mouse models (36) (A. Dash and D.G.G., unpublished observation) . The long latency APL that spontaneously develops in the PML͞RAR␣ transgenics (1) indicates that additional mutations are required for disease progression. In mice, the chromosomal changes observed with APL progression are varied but not random, suggesting that one or several of a particular subset of target genes must be mutated for progression to APL (8). The BMT model described here bypasses this acquisition step and demonstrates that FLT3-ITD can serve as a second hit in the development of APL in the mouse. The experiments presented here demonstrate cooperativity between FLT3-ITD and PML͞RAR␣ in the induction of APL, as evidenced by a decrease in latency, an increase in penetrance, and a change in disease phenotype compared with the controls with only PML͞ RAR␣ or FLT3-ITD. The histological and immunological phenotype of the APL observed with FLT3-ITD and PML͞RAR␣ is comparable to PML͞RAR␣ transgenic animals with a spontaneous APL. Additional experiments to assess the consequence of the reciprocal RAR␣͞PML in this model system where FLT3-ITD was transduced into PML͞RAR␣ and RAR␣͞PML double transgenic cells demonstrated no change in disease latency or phenotype when compared with FLT3-ITD-and PML͞RAR␣-induced disease (data not shown). Mutations in RAS have also been associated with human APLs and interestingly, do not coexist with FLT3 mutations (15, 37, 38) . These data suggest that there may be other activating mutations in tyrosine kinases or their downstream effectors in the remainder of APL cases.
Our model provides a useful tool for comparing the gene expression profiles between an APL caused by FLT3 and PML͞ RAR␣ and spontaneous AML in the PML͞RAR␣ transgenic and for studying the disease at a molecular level. Because PML͞RAR␣ is a well-characterized protein, it may be possible to understand some of the molecular events that occur in its cooperation with FLT3-ITD. Several promising FLT3 inhibitors are currently being developed (39, 40) (C.L.B., L.M.K., and D.G.G., unpublished observations). This model can also be used to test combinations of ATRA and specific FLT3 inhibitors in mice and may aid in the design of clinical trials in humans. Despite the success with treating APL patients with ATRA, Ϸ30% of patients will succumb to their disease or complications of therapy. In addition, ATRA therapy must currently be used in combination with anthracycline-based induction chemotherapy for prolonged disease-free survival. Depending on genotype, use of FLT3 inhibitors may improve the prognosis of APL patients who are refractory to ATRA treatment, or they may be useful in targeting or sensitizing the proliferating leukemia stem cells that may escape the effects of ATRA.
